The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review

Background Revefenacin (REV) is a novel once-daily long-acting muscarinic antagonist (LAMA) in the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). This systematic review incorporating a dose-response meta-analysis aimed to assess the efficacy and safety of REV. Met...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiaxing, Xie, Yihong, Kwong, Joey Sum-wing, Ge, Long, He, Rui, Zheng, Wenyi, Han, Jing, Zhang, Rui, Zhao, Huaye, He, Yuru, Li, Xiaosi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564370/
https://www.ncbi.nlm.nih.gov/pubmed/34744701
http://dx.doi.org/10.3389/fphar.2021.667027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564370/
https://www.ncbi.nlm.nih.gov/pubmed/34744701
http://dx.doi.org/10.3389/fphar.2021.667027

Ejemplares similares